Cholesterol metabolism in CKD

American Journal of Kidney Diseases

Volumn 66, Issue 6, 2015, Pages 1071-1082

  Reiss, Allison B ^a   Voloshyna, Iryna ^a   De Leon, Joshua ^a   Miyawaki, Nobuyuki ^a   Mattana, Joseph ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

atherosclerosis; cardiovascular disease (CVD); Cholesterol transport; chronic kidney disease (CKD); dyslipidemia; high density lipoprotein (HDL); inflammation; lipid lowering therapy; low density lipoprotein (LDL); nontraditional risk factor; reactive oxygen species (ROS); statin therapy; uremic toxins

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UREMIC TOXIN;

CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY DISEASE; DRUG EFFECT; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPOLIPEMIA; INFLAMMATION; LIPID ANALYSIS; LIPID STORAGE; META ANALYSIS (TOPIC); MICROENVIRONMENT; MULTICENTER STUDY (TOPIC); NONHUMAN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84948108393     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.06.028     Document Type: Review

References (129)

1. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, and et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension 42 5 2003 1050 1065
2. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 9731 2010 2073 2081
3. B.R. Hemmelgarn, B.J. Manns, A. Lloyd, et al. Alberta Kidney Disease Network Relation between kidney function, proteinuria, and adverse outcomes JAMA 303 5 2010 423 429
4. G. Manjunath, H. Tighiouart, H. Ibrahim, and et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J Am Coll Cardiol 41 1 2003 47 55
5. A.S. Go, G.M. Chertow, D. Fan, C.E. McCullock, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 13 2004 1296 1305
6. M. Chonchol, J. Whittle, A. Desbien, M.B. Orner, L.A. Petersen, and N.R. Kressin Chronic kidney disease is associated with angiographic coronary artery disease Am J Nephrol 28 2 2008 354 360
7. M.J. Sarnak, B.E. Coronado, T. Greene, and et al. Cardiovascular disease risk factors in chronic renal insufficiency Clin Nephrol 57 5 2002 327 335
8. C. Zoccali Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective Kidney Int 70 1 2006 26 33
9. D.E. Weiner, S. Tabatabai, H. Tighiouart, and et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease Am J Kidney Dis 48 3 2006 392 401
10. J.J. Carrero, and P. Stenvinkel Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal Clin J Am Soc Nephrol 4 1 suppl 1 2009 S49 S55
11. J. Shik, and P.S. Parfrey The clinical epidemiology of cardiac disease in chronic kidney disease Curr Opin Nephrol Hypertens 14 6 2005 550 557
12. V. Menon, A. Gul, and M.J. Sarnak Cardiovascular risk factors in chronic kidney disease Kidney Int 68 4 2005 1413 1418
13. P. Stenvinkel, J.J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3 2 2008 505 521
14. J. Malyszko Mechanism of endothelial dysfunction in chronic kidney disease Clin Chim Acta 411 19-20 2010 1412 1420
15. F. Stam, C. van Guldener, A. Becker, and et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn Study J Am Soc Nephrol 17 2 2006 537 545
16. S. Nakamura, H. Ishibashi-Ueda, S. Niizuma, F. Yoshihara, T. Horio, and Y. Kawano Coronary calcification in patients with chronic kidney disease and coronary artery disease Clin J Am Soc Nephrol 4 12 2009 1892 1900
17. T. Nakano, T. Ninomiya, S. Sumiyoshi, and et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama Study Am J Kidney Dis 55 1 2010 21 30
18. G.A. Block, P. Raggi, A. Bellasi, L. Kooienga, and D.M. Spiegel Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients Kidney Int 71 5 2007 438 441
19. K. Kato, T. Yonetsu, H. Jia, and et al. Nonculprit coronary plaque characteristics of chronic kidney disease Circ Cardiovasc Imaging 6 3 2013 448 456
20. E.S. Schaeffner, T. Kurth, G.C. Curhan, and et al. Cholesterol and the risk of renal dysfunction in apparently healthy men J Am Soc Nephrol 14 8 2003 2084 2091
21. N.D. Vaziri Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease J Ren Nutr 20 suppl 5 2010 S35 S43
22. N.D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Renal Physiol 290 2 2006 F262 F272
23. C. Baigent, M.J. Landray, C. Reith, et al. SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 9784 2011 2181 2192
24. M. Harbin, A. Amadio, and A. Tejani Critical appraisal of the SHARP trial: the results may be dull Clin Ther 36 12 2014 2112 2117
25. Y. Liu, J. Coresh, J.A. Eustace, and et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition JAMA 291 4 2004 451 459
26. A. Chait, R.L. Brazg, D.L. Tribble, and R.M. Krauss Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B Am J Med 94 4 1993 350 356
27. K. Kotani, K. Tsuzaki, N. Traniguchi, and N. Sakane LDL particle size and reactive oxygen metabolites in dyslipidemic patients Int J Prev Med 3 3 2012 160 166
28. D.L. Tribble, M. Rizzo, A. Chait, D.M. Lewis, P.J. Blanche, and R.M. Krauss Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins Am J Med 110 2 2001 103 110
29. P.O. Kwiterovich Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity Am J Cardiol 90 8A 2002 30i 47i
30. C.D. Gardner, S.P. Fortmann, and R.M. Krauss Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women JAMA 276 11 1996 875 881
31. N.F. Galeano, M. Al-Haideri, F. Keyserman, S.C. Rumsey, and R.J. Deckelbaum Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity J Lipid Res 39 6 1998 1263 1273
32. P.T. Williams, H.R. Superko, W.L. Haskell, and et al. Smallest LDL particles are most strongly related to coronary disease progression in men Arterioscler Thromb Vasc Biol 23 2 2003 314 321
33. P.T. Williams, X.Q. Zhao, S.M. Marcovina, J.D. Otvos, B.G. Brown, and R.M. Krauss Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease Atherosclerosis 233 2 2014 713 720
34. T. Shoji, S. Hatsuda, S. Tsuchikura, and et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis Atherosclerosis 202 2 2009 582 588
35. M. Chu, A.Y. Wang, I.H. Chan, S.H. Chui, and C.W. Lam Serum small-dense LDL abnormalities in chronic renal disease patients Br J Biomed Sci 69 3 2012 99 102
36. C.J. Deighan, M.J. Caslake, M. McConnell, J.M. Boulton-Jones, and C.J. Packard The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria Atherosclerosis 157 1 2001 211 220
37. E. Ritz, and C. Wanner Lipid changes and statins in chronic renal insufficiency J Am Soc Nephrol 17 12 suppl 3 2006 S226 S230
38. H.N. Ginsberg, N.A. Le, I.J. Goldberg, and et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo J Clin Invest 78 5 1986 1287 1295
39. J.R. Mead, S.A. Irvine, and D.P. Ramji Lipoprotein lipase: structure, function, regulation, and role in disease J Mol Med (Berl) 80 12 2002 753 769
40. B.G. Nordestgaard, and Tybjaerg-Hansen IDL, VLDL, chylomicrons and atherosclerosis Eur J Epidemiol 8 suppl 1 1992 92 98
41. J. Loscalzo Lipoprotein(a): a unique risk factor for atherothrombotic disease Arteriosclerosis 10 5 1990 672 679
42. H.J. Milionis, M.S. Elisaf, A. Tselepis, E. Bairaktari, S.A. Karabina, and K.C. Siamopoulos Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure Am J Kidney Dis 33 6 1999 1100 1106
43. A. Gaw, E. Boerwinkle, J.C. Cohen, and H.H. Hobbs Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus J Clin Invest 93 6 1994 2526 2534
44. F. Kronenberg, E. Kuen, E. Ritz, and et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure J Am Soc Nephrol 11 1 2000 105 115
45. S.C. Palmer, S.D. Navaneethan, J.C. Craig, and et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Cochrane Database Syst Rev 5 2014 CD007784
46. J. Rysz, A. Gluba-Brzózka, M. Banach, and A. Więcek Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge Int Urol Nephrol 47 5 2015 805 813
47. V. Chawla, T. Greene, G.J. Beck, and et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease Clin J Am Soc Nephrol 5 9 2010 1582 1587
48. M.G. Shlipak, L.F. Fried, M. Cushman, and et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors JAMA 293 14 2005 1737 1745
49. N.D. Vaziri, and K.H. Liang Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis Kidney Int 48 6 1995 1979 1985
50. N.D. Vaziri Molecular mechanisms of lipid disorders in nephrotic syndrome Kidney Int 63 5 2003 1964 1976
51. L. Rudel, and G. Shelness Cholesterol esters and atherosclerosis - a game of ACAT and mouse Nat Med 6 12 2000 1313 1314
52. N.D. Vaziri, and K.H. Liang Upregulation of acyl-coenzyme A: cholesterol acyltransferase (ACAT) in nephrotic syndrome Kidney Int 61 5 2002 1769 1775
53. N.D. Vaziri, K. Liang, and J.S. Parks Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure Kidney Int 59 6 2001 2192 2196
54. S. Kunnen, and M. Van Eck Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res 53 9 2012 1783 1799
55. G.F. Guarnieri, M. Moracchiello, L. Campanacci, and et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia Kidney Int Suppl 8 1978 S26 S30
56. L. Calabresi, S. Simonelli, P. Conca, and et al. Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease J Intern Med 277 5 2015 552 561
57. S. Beddhu, P.L. Kimmel, N. Ramkumar, and A.K. Cheung Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III) Am J Kidney Dis 46 4 2005 577 586
58. K.D. Navab, O. Elboudwarej, M. Gharif, and et al. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease Curr Pharm Des 7 1 2011 17 20
59. C.J. Fielding, and P.E. Fielding Molecular physiology of reverse cholesterol transport J Lipid Res 36 2 1995 211 228
60. I. Voloshyna, and A.B. Reiss The ABC transporters in lipid flux and atherosclerosis Prog Lipid Res 50 3 2011 213 224
61. M. Van Eck, M. Pennings, M. Hoekstra, R. Out, and T.J. Van Berkel Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis Curr Opin Lipidol 16 3 2005 307 315
62. M. Bodzioch, E. Orsó, J. Klucken, and et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease Nat Genet 22 4 1999 347 351
63. I.C. Gelissen, M. Harris, K.A. Rye, and et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I Arterioscler Thromb Vasc Biol 26 3 2006 534 540
64. X. Wang, H.L. Collins, M. Ranalletta, and et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo J Clin Invest 117 8 2007 2216 2224
65. C. Mineo, and P.W. Shaul Functions of scavenger receptor class B, type I in atherosclerosis Curr Opin Lipidol 23 5 2012 487 493
66. P.J. Barter, H.B. Brewer Jr., M.J. Chapman, C.H. Hennekens, D.J. Rader, and A.R. Tall Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 2 2003 160 167
67. H. Kimura, R. Miyazaki, T. Imura, and et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels Kidney Int 64 5 2003 1829 1837
68. H. Cardinal, M.A. Raymond, M.J. Hebert, and F. Madore Uraemic plasma decreases the expression of ABCA1, ABCG1 and cell-cycle genes in human coronary arterial endothelial cells Nephrol Dial Transplant 22 2 2007 409 416
69. P.O. Attman, P. Alaupovic, and A. Gustafson Serum apolipoprotein profile of patients with chronic renal failure Kidney Int 32 3 1987 368 375
70. J.C. Lo, A.S. Go, M. Chandra, D. Fan, and G.A. Kaysen GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD Am J Kidney Dis 50 4 2007 552 558
71. K.S. Rogacev, A.M. Zawada, I. Emrich, and et al. Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in chronic kidney disease Arterioscler Thromb Vasc Biol 34 9 2014 2120 2127
72. J.E. Feig, R. Shamir, and E.A. Fisher Atheroprotective effects of HDL: beyond reverse cholesterol transport Curr Drug Targets 9 3 2008 196 203
73. P.J. Barter, S. Nicholls, K.-A. Rye, G. Anantharamaiah, M. Navab, and A.M. Fogelman Anti-inflammatory properties of HDL Circ Res 95 8 2004 764 772
74. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 12 2006 3090 3100
75. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, T. Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 24 2011 2255 2267
76. B.F. Voight, G.M. Peloso, M. Orho-Melander, and et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study Lancet 380 9841 2012 572 580
77. S. Dodani, D.G. Grice, and S. Joshi Is HDL function as important as HDL quantity in the coronary artery disease risk assessment? J Clin Lipidol 3 2 2009 70 77
78. V. Kon, T.A. Ikizler, and S. Fazio Importance of high-density lipoprotein quality: evidence from chronic kidney disease Curr Opin Nephrol Hypertens 22 3 2013 259 265
79. S.B. Alabakovska, B.B. Todorova, D.D. Labudovic, and K.N. Tosheska Related LDL and HDL subclass distribution in patients with end-stage renal diseases Clin Biochem 35 3 2002 211 216
80. M. Holzer, R. Birner-Gruenberger, T. Stojakovic, and et al. Uremia alters HDL composition and function J Am Soc Nephrol 22 9 2011 1631 1641
81. M. Dirican, R. Akca, E. Sarandol, and K. Dilek Serum paraoxonase activity in uremic predialysis and hemodialysis patients J Nephrol 17 6 2004 813 818
82. T.F. Dantoine, J. Debord, J.P. Charmes, and et al. Decrease of serum paraoxonase activity in chronic renal failure J Am Soc Nephrol 9 11 1998 2082 2088
83. T. Weichhart, C. Kopecky, M. Kubicek, and et al. Serum amyloid A in uremic HDL promotes inflammation J Am Soc Nephrol 23 5 2012 934 947
84. E. Malle, G. Marsche, U. Panzenboeck, and W. Sattler Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins Arch Biochem Biophys 445 2 2006 245 255
85. M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo, and B.N. La Du Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase J Clin Invest 101 8 1998 1581 1590
86. Y. Liu, B. Mackness, and M. Mackness Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress Free Radic Biol Med 45 6 2008 743 748
87. M. Rosenblat, J. Vaya, D. Shih, and M. Aviram Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine Atherosclerosis 179 1 2005 69 77
88. A. Rohatgi, A. Khera, J.D. Berry, and et al. HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 371 25 2014 2383 2393
89. S. Yamamoto, P.G. Yancey, T.A. Ikizler, and et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis J Am Coll Cardiol 60 23 2012 2372 2379
90. J.E. Deanfield, J.P. Halcox, and T.J. Rabelink Endothelial function and dysfunction: testing and clinical relevance Circulation 115 10 2007 1285 1295
91. C. Besler, K. Heinrich, L. Rohrer, and et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 7 2011 2693 2708
92. T. Speer, L. Rohrer, P. Blyszczuk, and et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2 Immunity 38 4 2013 754 768
93. S. Zewinger, T. Speer, M.E. Kleber, and et al. HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction J Am Soc Nephrol 25 5 2014 1073 1082
94. M. Bonomini, M. Reale, P. Santarelli, and et al. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients Nephron 79 4 1998 399 407
95. M. Annuk, B. Fellström, O. Akerblom, K. Zilmer, T. Vihalemm, and M. Zilmer Oxidative stress markers in pre-uremic patients Clin Nephrol 56 4 2001 308 314
96. T. Niwa Indoxyl sulfate is a nephro-vascular toxin J Ren Nutr 20 suppl 5 2010 S2 S6
97. F.C. Barreto, D.V. Barreto, S. Liabeuf, et al. European Uremic Toxin Work Group (EUTox) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients Clin J Am Soc Nephrol 4 10 2009 1551 1558
98. Z. Tumur, H. Shimizu, A. Enomoto, H. Miyazaki, and T. Niwa Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation Am J Nephrol 31 5 2010 435 441
99. L. Dou, E. Bertrand, C. Cerini, and et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair Kidney Int 65 2 2004 442 451
100. H. Yamamoto, S. Tsuruoka, T. Ioka, and et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells Kidney Int 69 10 2006 1780 1785
101. G. Muteliefu, A. Enomoto, and T. Niwa Indoxyl sulfate promotes proliferation of human aortic smooth muscle cells by inducing oxidative stress J Ren Nutr 19 1 2009 29 32
102. A. Atamer, Y. Kocyigit, S.A. Ecder, and et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease J Nephrol 21 6 2008 924 930
103. T. Amaki, T. Suzuki, F. Nakamura, and et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease Heart 90 10 2004 1211 1213
104. E. Ok, A.G. Basnakian, E.O. Apostolov, Y.M. Barri, and S.V. Shah Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease Kidney Int 68 1 2005 173 178
105. E.O. Apostolov, D. Ray, A.V. Savenka, S.V. Shah, and A.G. Basnakian Chronic uremia stimulates LDL carbamylation and atherosclerosis J Am Soc Nephrol 21 11 2010 1852 1857
106. T. Speer, F.O. Owala, E.W. Holy, and et al. Carbamylated low-density lipoprotein induces endothelial dysfunction Eur Heart J 35 43 2014 3021 3032
107. E.O. Apostolov, D. Ray, W.M. Alobuia, and et al. Endonuclease G mediates endothelial cell death induced by carbamylated LDL Am J Physiol Heart Circ Physiol 300 6 2011 H1997 H2004
108. G. Asci, A. Basci, S.V. Shah, and et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells Nephrology (Carlton) 13 6 2008 480 486
109. E.O. Apostolov, S.V. Shah, E. Ok, and A.G. Basnakian Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 Arterioscler Thromb Vasc Biol 27 4 2007 826 832
110. B. Hartmann, D. Czock, and F. Keller Drug therapy in patients with chronic renal failure Dtsch Arztebl Int 107 37 2010 647 655
111. C. Wanner, M. Tonelli Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient Kidney Int 85 6 2014 1303 1309
112. M.J. Sarnak, R. Bloom, P. Muntner, and et al. KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD Am J Kidney Dis 65 3 2015 354 366
113. W. Hou, J. Lv, V. Perkovic, and et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur Heart J 34 24 2013 1807 1817
114. G.F. Strippoli, S.D. Navaneethan, D.W. Johnson, and et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 336 7645 2008 645 651
115. P.A. McCullough, and M.J. Di Loreto Fibrates and cardiorenal outcomes J Am Cardiol 60 20 2012 2072 2073
116. J. Wu, Y. Song, H. Li, and J. Chen Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report Eur J Clin Pharmacol 65 12 2009 1169 1174
117. M.H. Ahmed Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials Ren Fail 32 5 2010 642 646
118. R.S. Kalil, J.H. Wang, I.H. de Boer, and et al. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial Kidney Int 87 6 2015 1250 1257
119. A.C. Ricardo, C.A. Anderson, W. Yang, et al. CRIC Study Investigators Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study Am J Kidney Dis 65 3 2015 412 424
120. Y.A. Salmean, G.A. Zello, and W.J. Dahl Foods with added fiber improve stool frequency in individuals with chronic kidney disease with no impact on appetite or overall quality of life BMC Res Notes 6 2013 510
121. I. Voloshyna, O. Hai, M.J. Littlefield, S. Carsons, and A.B. Reiss Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine Eur J Pharmacol 698 1-3 2013 299 309
122. H.Z. Toklu, O. Sehirli, M. Erşahin, and et al. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats J Pharm Pharmacol 62 12 2010 1784 1793
123. C.H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J.L. Beaudeux Resveratrol bioavailability and toxicity in humans Mol Nutr Food Res 54 1 2010 7 16
124. Y. Zuo, P. Yancey, I. Castro, and et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1 Arterioscler Thromb Vasc Biol 29 9 2009 1277 1282
125. O.E. Ayodele, and C.O. Alebiosu Burden of chronic kidney disease: an international perspective Adv Chronic Kidney Dis 17 3 2010 215 224
126. M. Tonelli, P. Muntner, A. Lloyd, et al. Alberta Kidney Disease Network Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 380 9844 2012 807 814
127. J. Coresh, E. Selvin, L.A. Stevens, and et al. Prevalence of chronic kidney disease in the United States JAMA 298 17 2007 2038 2047
128. P. Stenvinkel, R. Pecoits-Filho, and B. Lindholm Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem J Am Soc Nephrol 14 7 2003 1927 1939
129. N. Bansal Clinically silent myocardial infarctions in the CKD community Nephrol Dial Transplant 27 9 2012 3387 3391